These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8152363)

  • 21. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension.
    Johannesson M; Meltzer D; O'Conor RM
    Med Decis Making; 1997; 17(4):382-9. PubMed ID: 9343796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On sale: future health care. The paradox of discounting.
    Ganiats TG
    West J Med; 1992 May; 156(5):550-3. PubMed ID: 1595287
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong.
    Chau J; Cheung BM; McGhee SM; Lauder IJ; Lau CP; Kumana CR
    Hong Kong Med J; 2001 Dec; 7(4):360-8. PubMed ID: 11773670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating mild to moderate hypertension: cost-effectiveness and policy implications.
    Kawachi I; Malcolm LA
    J Cardiovasc Pharmacol; 1990; 16 Suppl 7():S126-8. PubMed ID: 1708013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
    McInnes G; Burke TA; Carides G
    J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of targeted HIV prevention interventions for female sex workers in India.
    Prinja S; Bahuguna P; Rudra S; Gupta I; Kaur M; Mehendale SM; Chatterjee S; Panda S; Kumar R
    Sex Transm Infect; 2011 Jun; 87(4):354-61. PubMed ID: 21447514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of testing for breast cancer susceptibility genes.
    Holland ML; Huston A; Noyes K
    Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [How does one calculate life expectancy in relation to risk factors?].
    Siebert U; Hölzel D
    Internist (Berl); 1999 Mar; 40(3):319-22. PubMed ID: 10205760
    [No Abstract]   [Full Text] [Related]  

  • 29. [Preventing fatal diseases increases health care costs].
    Moatti JP
    Rev Epidemiol Sante Publique; 1998 Jun; 46(3):245-6. PubMed ID: 9690292
    [No Abstract]   [Full Text] [Related]  

  • 30. Richard Milne responds to PHARMAC on discounting future health benefits and costs.
    Milne R
    N Z Med J; 2005 Aug; 118(1220):U1620. PubMed ID: 16132078
    [No Abstract]   [Full Text] [Related]  

  • 31. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.
    Campos NG; Salomon JA; Servoss JC; Nunes DP; Samet JH; Freedberg KA; Goldie SJ
    Am J Med; 2007 Mar; 120(3):272-9. PubMed ID: 17349451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lifetime costs for preventive medical services: a model.
    Filak AT; Ricer JS; Ricer RE
    J Fam Pract; 1999 Sep; 48(9):706-10. PubMed ID: 10498077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology.
    Nelson CL; Sun JL; Tsiatis AA; Mark DB
    Stat Med; 2008 Nov; 27(26):5525-55. PubMed ID: 18613251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What to do when the patient outlives the literature, or DEALE-ing with a full deck.
    Moroff SV; Pauker SG
    Med Decis Making; 1983; 3(3):313-38. PubMed ID: 6645821
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the effectiveness of disease and injury prevention programs: costs and consequences.
    MMWR Recomm Rep; 1995 Aug; 44(RR-10):1-10. PubMed ID: 7565538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of blindness prevention by the Onchocerciasis Control Programme in Upper Volta.
    Prost A; Prescott N
    Bull World Health Organ; 1984; 62(5):795-802. PubMed ID: 6439428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.